HomeScientific References

Scientific References

Scientific References:

Restoring the Extracellular Matrix: A Neuroprotective Role for Collagen Mimetic Peptides in Experimental Glaucoma.  Nolan R. McGrady, Silvia Pasini, Robert O. Baratta, Brian J. Del Buono, Eric Schlumpf and David J. Calkins. (2021) Frontiers in Pharmacology, 02 November, 2021.

Intraocular Delivery of a Collagen Mimetic Peptide Repairs Retinal Ganglion Cell Axons in Chronic and Acute Injury Models.  Marcio Ribeiro, Nolan R. McGrady, Robert O. Baratta, Brian J. Del Buono, Eric Schlumpf and David J. Calkins. (2022)  International Journal of Molecular Sciences, Pathophysiologic Mechanisms of Eye Diseases and Novel Therapeutic Approaches Special Issue, 08 March, 2022.

Efraim Y, Chen FYT, Stashko C, Cheong KN, Gaylord E, McNamara N, Knox SM. Alterations in corneal biomechanics underlie early stages of autoimmune-mediated dry eye disease. J Autoimmun. 2020 Nov;114:102500. doi: 10.1016/j.jaut.2020.102500. Epub 2020 Jun 18. PMID: 32565048; PMCID: PMC8269964.

Corneal Collagen as a Potential Therapeutic Target in Dry Eye Disease. R.O. Baratta, E. Schlumpf, B.J. DelBuono, S. De Lorey, and D.J. Calkins.  (2021) Survey of Ophthalmology May/June.

DOI: 10.1016/j.survophthal.2021.04.006

Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration.  R.O. Baratta, B. J. Del Buono, E. Schlumpf,  B.Ceresa, and D.J. Calkins.  Frontiers in Pharmacology 2021 (12) 1-8.

Interstrand dipole–dipole interactions can stabilize the collagen triple helix. Matthew D. Shoulders and Ronald T. Raines (2011). Journal of Biological Chemistry 286, 22905–22912.

doi: 10.1074/jbc.M110.199984

Stereo-electronic and steric effects in side chains pre-organize a protein main chain. Matthew D. Shoulders, Kenneth A. Satyshur, Katrina T. Forest, and Ronald T. Raines (2010). Proc. National Academy of Sciences (PNAS)  107 (2) 559-564.

Collagen Structure-Function Mapping Informs Applications for Regenerative Medicine.  J.D. San Antonio, O. Jacenko, A. Fertala, and J.P.R.O. Orgel. (2021) BioEngineering 8 (1), 3.

Peptides that anneal to natural collagen in vitro and ex vivo. Sayani Chattopadhyay, Christopher J. Murphy, Jonathan F. McAnulty, and Ronald T. Raines (2012). Organic & Biomolecular Chemistry 10, 5892–5897. DOI


Optimal interstrand bridges for collagen-like biomaterials. I. Caglar Tanrikulu and Ronald T. Raines (2014). Journal of the American Chemical Society 136, 13490–13493.

DOI: 10.1021/ja505426g

The nπ* interaction. Robert W. Newberry and Ronald T. Raines Accounts of Chemical Research (2017) 50, 1838–1846.

Embryonic Chick Corneal Epithelium: A Model System for Exploring Cell-Matrix Interactions.  K.K.H. Svoboda, D.A. Fischman, and M.K. Gordon (2008) Developmental Dynamics, (237) 2667-2675.


Biology of Corneal Fibrosis: soluble mediators, integrins, and extracellular vesicles. Tina McKay, Audrey Hutcheon and James Zieske. (2019). Eye, 34, 1-8.


Transmembrane Collagen Receptors. Birgit Leitinger (2011) Annual Review of Cell and Developmental Biology. 27, 265-290

Collagen-based biomaterials for wound healing. Sayani Chattopadhyay and Ronald T. Raines (2014). Biopolymers 101, 821–833.


Anchoring a cytoactive factor in a wound bed promotes healing. Sayani Chattopadhyay, Kathleen M. Gutherie, Leandro Teixeira, Christopher J. Murphy, Richard R. Dubielzig, Jonathan F. McAnulty, and Ronald T. Raines (2016). Journal of Tissue Engineering and Regenerative Medicine 10, 1012–1020.


Cyclic peptide mimetic of damaged collagen. Aubrey J. Ellison, I. Caglar Tanrikulu, Jesús M. Dones, and Ronald T. Raines (2020). Biomacromolecules 21, 1539–1547.


The dynamic nature of Bruch’s membrane. JC Booj, DC Baas, J Beisekeeva, TGMF Gorgels and AAB Bergen. Prog Retin Eye Res 2010 Jan; 29 (1) 1-18.                                       doi: 10.1016/j.preteyeres.2009.08.003.

Nita, M., Strazalka-Mrozik, B., Grzybowski, A, Mazurek, U,. and Romaniuk, W. Age-related macular degeneration and changes in the extracellular matrix. Med Sci Monit. 2014; 20:1003-1016.


Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents through license. At Stuart Therapeutics, we are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications. We are interested in strategic partner relationships that will extend and accelerate our impact.